Navigation Links
Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
Date:9/8/2010

SAN FRANCISCO and ILLKIRCH, France, Sept. 8 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.  

JX-594, Jennerex's lead cancer biotherapeutic product, has shown anticancer activity and a well-tolerated safety profile in Phase 1 and Phase 2 clinical trials to date(1). Objective tumor response has been demonstrated in a variety of cancers including liver, colon, kidney, lung and melanoma.

Jennerex has awarded Transgene exclusive rights to develop and commercialize JX-594 in Europe, the CIS and the Middle East.  Jennerex and Transgene will co-develop JX-594 worldwide, with Transgene responsible for development costs and for clinical development in its licensed territories, pursuant to the JX-594 global development plan. Transgene is responsible for commercialization and has the right to manufacture JX-594 in the Transgene territory. As part of this agreement Transgene has made an upfront equity investment in Jennerex. Jennerex is further eligible to earn a total of up to $116 million in development and registration milestones as well as double digit royalties on a tiered structure. In addition, Jennerex has an option for co-promotion and profit-sharing in the five major European countries.

The development plan will focus initially on Hepatocellular Carcinoma (HCC), both in first line and in second line, and on colorectal cancer. Transgene and Jennerex intend to initiate a large randomized controlled phase 2b/3 clinical program in HCC patients. 
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
2. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
3. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
4. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
7. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
8. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
9. Sigma® Life Science Enters Genetically Modified Cell Market
10. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
11. Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 AACC welcomed thousands ... 2015 AACC Annual Meeting & Clinical Lab Expo ... 26–30. The meeting showcased revolutionary advancements in clinical ... of healthcare providers to diagnose patients quickly and ... treatment. As of Wednesday, July ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative ... study of its canine osteoarthritis stem cell product, currently under development for FDA ... and will be marketed in the US by Aratana. This product, termed AT-016, ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against ... were $697 million compared to $701 million in the ... and changes in foreign currency exchange rates decreased sales ... , By business unit, organic sales growth was 6% ... Commercial. , Reported diluted EPS was $0.98 compared ...
(Date:7/29/2015)... 30, 2015 Sanofi, un ... ses résultats pour le premier semestre 2015. Le ... résultats. Visionner l,interview vidéo et lire ... Au sommaire de l,interview :  ... de croissance - Diabète ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Feb. 11 Elekta Neuromag(R),the world-leading equipment ... (MEG) technology, has been ordered by The,Nebraska ... http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO ), With a reputation ... Nebraska Medical Center has earned J.D. Power ...
... Feb. 11 AtriCure, Inc.,(Nasdaq: ATRC ), ... cardiac surgical,ablation products, today announced that the first ... Dr. Richard Kaplon, a,well-known cardiac surgeon, performed the ... The purpose of the ABLATE clinical trial is ...
... Direct-To-Consumer Campaign of a Living ... ... Inc., the first,company to successfully mass-produce living regenerative medicine products,is ... campaign for a living cell-based therapy. As the first,bio-engineered living ...
Cached Biology Technology:Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center 2Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 2AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 4Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers 2Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers 3Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers 4
(Date:7/31/2015)... 31 de julio de 2015 La 10 th ... celebrará por medio de BGI del 22 al 25 de octubre ... Este año, la conferencia celebra su décimo aniversario. ... convertido en una de las reuniones anuales más influyentes del ... las reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... reasons why early humans the so-called hominins began ... children was a factor, as has previously been suggested. ... cling to their parents in the way that young apes ... explanation as to why humans became bipedal. But University ...
... 2008) Researchers seeking new and more abundant ... have identified a potentially unlimited, noncontroversial, easily collectable, and ... cells - cells that are present in connective tissues ... the uterus. When the fresh growth of tissue and ...
... professor of electrical and computer engineering at McMaster ... Award for his work in electrical, electronic and ... to outstanding scientists and scholars whose fundamental discoveries, ... impact on their own discipline and who are ...
Cached Biology News:Early parents didn't stand for weighty kids 2Menstrual blood -- a valuable source of multipotential stem cells? 2McMaster University engineering professor receives Humboldt Research Award 2
Monocyte-derived dendritic cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Biology Products: